Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00026910
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2001-11-14
Brief Title:
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkins Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2002-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Although the causes of clinical drug resistance in non-Hodgkins lymphomas NHL are unknown in vitro studies suggest that abnormalities of the cell cycle and mechanisms of apoptosis may play an important role Clinical studies have now shown that p53 bcl-2 and tumor proliferation all have significant effects on clinical drug resistance To further investigate the role of genes that control the cell cycle and apoptosis we wish to correlate the expression of multiple molecular targets including but not restricted to bcl-2 BAX bcl-6 MIB-1 p53 p21 p27 p16 cyclin D1 cyclin A cyclin E mdm-2 cpp 32 mcl-1 EBER-1 ALK and a panel of B T and other cell lineage markers involving these pathways with clinical outcome following treatment with combination chemotherapy All clinical data and tissue samples for this study will come from patients who have been previously enrolled on two protocols for the initial treatment of aggressive lymphomas No new patients will be enrolled for this study
Detailed Description:
Although the causes of clinical drug resistance in non-Hodgkins lymphomas NHL are unknown in vitro studies suggest that abnormalities of the cell cycle and mechanisms of apoptosis may play an important role Clinical studies have now shown that p53 bcl-2 and tumor proliferation all have significant effects on clinical drug resistance To further investigate the role of genes that control the cell cycle and apoptosis we wish to correlate the expression of multiple molecular targets using immunohistochemistry and cDNA microarray expression profiling including but not restricted to bcl-2 BAX bcl-6 MIB-1 p53 p21 p27 p16 cyclin D1 cyclin A cyclin E mdm-2 cpp 32 mcl-1 EBER-1 ALK and a panel of B T and other cell lineage markers involving these pathways with clinical outcome following treatment with combination chemotherapy All clinical data and tissue samples for this study will come from patients who have been previously enrolled on two protocols for the initial treatment of aggressive lymphomas No new patients will be enrolled for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 98-C-0136 | None | None | None |